ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The oncology research firm BeiGene has raised $97 million from private equity investors to sustain existing drug research programs. The company has three cancer drug candidates undergoing Phase I clinical trials and several other programs at the preclinical stage. Based in Beijing and employing 170 people, BeiGene is headed by the U.S. entrepreneur John V. Oyler, who previously launched the drug discovery services firm BioDuro in China.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X